Clinical Trial Update: FLT3 Ligand Immunotherapy and Stereotactic Radiotherapy for Advanced Non-small Cell Lung Cancer [Phase 2]

View source ↗

Summary

Phase 2 clinical trial evaluating FLT3 ligand immunotherapy in combination with stereotactic radiotherapy for advanced non-small cell lung cancer has completed …

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Non-small Cell Lung Cancer

Drugs mentioned

• FLT3 Ligand Immunotherapy (FLT3 ligand)

Snippet

Sponsor: Albert Einstein College of Medicine | Conditions: Non-small Cell Lung Cancer (NSCLC) | Phase 2 | Status: COMPLETED | Results posted: 2024-06-06